TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Drug Use for Elderly Heart Failure Patients
Brief Summary: The aims of this randomized, clinical trial are to develop and test a multileveled pharmacy-based program to improve the care of patients with heart failure. Risk factors for deterioration of heart failure will be determined including poor adherence to medication.


Options:
A: Blood Pressure and Hemaglobin A1c
B: Adherence to medication; self-reported current use of antiplatelet, statin and combination (≥ 2) blood pressure lowering therapy (End of trial follow-up); Change in blood pressure (End of trial follow-up); Change in LDL cholesterol (End of trial follow-up)
C: Medication adherence (At Month 12)
D: Medication adherence; Exacerbation of heart failure; Health-related quality of life

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Drug Use for Elderly Heart Failure Patients
Brief Summary: The aims of this randomized, clinical trial are to develop and test a multileveled pharmacy-based program to improve the care of patients with heart failure. Risk factors for deterioration of heart failure will be determined including poor adherence to medication.


Options:
A: Improvement of drug prescribing (Participants will be followed for the duration of hospital stay, an expected average of 12 days)
B: Neuropsychiatric symptoms (9 months); Quality of life (9 months)
C: Changes in a set of predefined quality indicators measuring appropriateness of prescriptions for elderly out-patients (1 year)
D: Medication adherence; Exacerbation of heart failure; Health-related quality of life

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Drug Use for Elderly Heart Failure Patients
Brief Summary: The aims of this randomized, clinical trial are to develop and test a multileveled pharmacy-based program to improve the care of patients with heart failure. Risk factors for deterioration of heart failure will be determined including poor adherence to medication.


Options:
A: Adherence to hypertension guidelines (Measured for two 6 month periods: the first is prior to the participant's enrollment in the study and the second is while the participant is enrolled in the study)
B: The number of patients that complete recommended laboratory monitoring within one week and twenty five days after intervention.; The study will evaluate the time to completion of the recommended labs.; The study will also evaluate PCP and patient experiences with the interventions in order to refine the interventions in the future.
C: Medication adherence; Exacerbation of heart failure; Health-related quality of life
D: Blood pressure control (Measured by zero blood pressure measurements at baseline and 2, 4, 6, 8, and 9 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
Brief Summary: The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.


Options:
A: Pathologic complete response
B: Recurrence-free survival
C: Relapse-free Survival Rates at 2.4 Years (randomization until date of first event, or date last known to be event free if no event was reported (up to 5 years))
D: Overall Survival (From date of randomization until death from any cause)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Medication Use in Patients With Hypertension
Brief Summary: The purpose of this trial is to determine whether minority and low-income patients with high blood pressure take their medications better when they are helped by a pharmacist and provided with special medication packaging and information aimed at persons with low health literacy.


Options:
A: Number Who Discontinued Medication Within First 6 Study Months (Measured at Six Months)
B: Adherence to blood pressure medications; Blood pressure control
C: Change from baseline in Fall Risk Assessment Tool (FRAT) score (Change from baseline in FRAT score at 3 months); Change from baseline in Fall Risk Assessment Tool (FRAT) score (Change from baseline in FRAT score at 6 months); Change from baseline in Fall Risk Assessment Tool (FRAT) score (Change from baseline in FRAT score at 12 months); Change from baseline in fall rate (Change from baseline in fall rate at 3 months); Change from baseline in fall rate (Change from baseline in fall rate at 6 months); Change from baseline in fall rate (Change from baseline in fall rate at 12 months)
D: Successful medication discontinuation (4 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study
Brief Summary: Osteoporosis is a common and progressive condition that leads to broken bones (fractures), which cause pain, disability, deformity, and even death. There are new treatments available that can decrease the risk of a fracture by 50%, and the people who benefit the most are those with osteoporosis who have already had a fracture, like a vertebral (spine) fracture. Vertebral fractures are usually "silent," and \~20% of people over the age of 60 years have had one although they don't know it. Many of these people have had chest x-rays done for other reasons, and these x-rays can incidentally detect these silent fractures. Although most people with a vertebral fracture should be tested and treated for osteoporosis, studies demonstrate that less than one-quarter of older people with a vertebral fracture are ever investigated or even treated. This reflects a gap between evidence-based best practice and everyday practice in the community. The proposed research addresses this care-gap by using a quality improvement intervention that uses chest x-rays done in the Emergency Department to remind family physicians about osteoporosis while providing them with evidence-based treatment guidelines - with or without educating and empowering patients about osteoporosis. The effectiveness of this intervention will be compared to usual care in a controlled trial. The intent of this research is to improve quality of care for patients at high risk of fracture, by increasing rates of testing and treatment of osteoporosis.


Options:
A: Adherence to guidelines G10 and G17 of the 2003 International Consensus Guidelines on nonvariceal upper GI bleeding. (1 year)
B: Increased use of proven efficacious osteoporosis treatment within six months of study enrollment, defined as: hormone therapy, a bisphosphonate, raloxifene, or calcitonin.
C: Composite measure representing improvement in cholesterol-related secondary prevention consisting of (1) provision of a statin sample (2) provision of a statin prescription or (3) dosage increase of a statin within the first 6 months post-angiogram.
D: The primary outcome is the proportion of patients starting prescription osteoporosis treatment within 3 months of fracture recognition (3 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study
Brief Summary: Osteoporosis is a common and progressive condition that leads to broken bones (fractures), which cause pain, disability, deformity, and even death. There are new treatments available that can decrease the risk of a fracture by 50%, and the people who benefit the most are those with osteoporosis who have already had a fracture, like a vertebral (spine) fracture. Vertebral fractures are usually "silent," and \~20% of people over the age of 60 years have had one although they don't know it. Many of these people have had chest x-rays done for other reasons, and these x-rays can incidentally detect these silent fractures. Although most people with a vertebral fracture should be tested and treated for osteoporosis, studies demonstrate that less than one-quarter of older people with a vertebral fracture are ever investigated or even treated. This reflects a gap between evidence-based best practice and everyday practice in the community. The proposed research addresses this care-gap by using a quality improvement intervention that uses chest x-rays done in the Emergency Department to remind family physicians about osteoporosis while providing them with evidence-based treatment guidelines - with or without educating and empowering patients about osteoporosis. The effectiveness of this intervention will be compared to usual care in a controlled trial. The intent of this research is to improve quality of care for patients at high risk of fracture, by increasing rates of testing and treatment of osteoporosis.


Options:
A: Total number of split tests performed in study period. (January - April 2011)
B: The primary outcome is the proportion of patients starting prescription osteoporosis treatment within 3 months of fracture recognition (3 months)
C: The primary outcome measure will be the "improvement" of prescribing for efficacious therapies in patients with a chronic cardiovascular disease within six months of the intervention.
D: Short-term adherence to CRC screening (From randomization to the end of 2 years); Long-term adherence to CRC screening (From randomization to the end of 9 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Strength Training Effectiveness Post-Stroke (STEPS)
Brief Summary: The purpose of this study is to determine if treadmill training with body weight-support (BWST) is more effective at improving walking in individuals post-stroke than a resisted leg-cycling exercise program. In addition, we want to determine if training programs that combine leg strength training to treadmill walking provide an additional benefit to post-stroke walking outcomes.


Options:
A: Change from Baseline in the gait velocity (Baseline, immediately after and six weeks after training cessation.)
B: Improvement ín motor function among patients in each group
C: walking speed (meters/second); walking distance (distance walked in 6-minutes)
D: Proportion of participants walking independently (defined for the purposes of this study as'being able to walk 15 m continuously across flat ground without any aids'). (Within 6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Strength Training Effectiveness Post-Stroke (STEPS)
Brief Summary: The purpose of this study is to determine if treadmill training with body weight-support (BWST) is more effective at improving walking in individuals post-stroke than a resisted leg-cycling exercise program. In addition, we want to determine if training programs that combine leg strength training to treadmill walking provide an additional benefit to post-stroke walking outcomes.


Options:
A: Community Balance and Mobility Scale (Pre treatment and Post treatment (6 weeks))
B: walking speed (meters/second); walking distance (distance walked in 6-minutes)
C: Physical Function as Measured by Telephone Version of FIM (6-month)
D: Percentage of Patients Who Successfully Improved Functional Level of Walking at 1 Year Post-stroke (12 months post-stroke); Walking Speed: Measured During a 10-meter Walk (Baseline and 12 months post-stroke)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Strength Training Effectiveness Post-Stroke (STEPS)
Brief Summary: The purpose of this study is to determine if treadmill training with body weight-support (BWST) is more effective at improving walking in individuals post-stroke than a resisted leg-cycling exercise program. In addition, we want to determine if training programs that combine leg strength training to treadmill walking provide an additional benefit to post-stroke walking outcomes.


Options:
A: Improvement ín motor function among patients in each group
B: Percentage of Patients Who Successfully Improved Functional Level of Walking at 1 Year Post-stroke (12 months post-stroke); Walking Speed: Measured During a 10-meter Walk (Baseline and 12 months post-stroke)
C: walking speed (meters/second); walking distance (distance walked in 6-minutes)
D: Gait speed: measured with the comfortable 10-meter walk test (The outcome measure will be assessed at pre-test (within 1-week before beginning the intervention), post-test (within 1-week after completing the 2-week intervention period) and at retention (3-months following completion of the intervention).)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Drug and Non-Drug Treatment of Pediatric Chronic Headache
Brief Summary: The purpose of this trial is to evaluate the efficacy of combined behavioral and pharmacological treatment on chronic daily headache in children ages 10 to 17.


Options:
A: Adherence (beginning at baseline - week 20)
B: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
C: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
D: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) (Baseline (prior to randomization) and 3 months after intervention)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Drug and Non-Drug Treatment of Pediatric Chronic Headache
Brief Summary: The purpose of this trial is to evaluate the efficacy of combined behavioral and pharmacological treatment on chronic daily headache in children ages 10 to 17.


Options:
A: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
B: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
C: symptoms of recurrent abdominal pain (measured one week following treatment and again in 3, 6 and 12 months); disability (measured one week following treatment and again in 3, 6 and 12 months)
D: Abdominal Pain Index (Baseline, 1 week post treatment session 3, 3 months post treatment session 3, 6 months post treatment session 3, 12 months post treatment session 3)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Drug and Non-Drug Treatment of Pediatric Chronic Headache
Brief Summary: The purpose of this trial is to evaluate the efficacy of combined behavioral and pharmacological treatment on chronic daily headache in children ages 10 to 17.


Options:
A: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
B: symptoms of recurrent abdominal pain (measured one week following treatment and again in 3, 6 and 12 months); disability (measured one week following treatment and again in 3, 6 and 12 months)
C: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
D: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) (Baseline (prior to randomization) and 3 months after intervention)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients
Brief Summary: The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).


Options:
A: Use of inhaled corticosteroid (ICS).
B: determine the proportion of patients who achieve well-controlled asthma with SLIT compared to placebo (September 2009)
C: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion (Three years (36 months) after Treatment Completion)
D: change in symptom score active versus placebo

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients
Brief Summary: The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).


Options:
A: Use of inhaled corticosteroid (ICS).
B: Changes of Symptom-Medication-Score (After 1 year of treatment)
C: Recording of allergy symptoms (Grass pollen season 2007)
D: Combined Score (CS) (Pollen period (average of 42.8 days))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Brief Summary: The purpose of this study is to compare the effectiveness of treating acute ischemic stroke with mechanical embolectomy using the Merci Retriever or the Penumbra System within 8 hours of symptom onset to standard medical treatment, and to identify people who might benefit from mechanical embolectomy by the appearance of stroke on multimodal computerized tomography (CT) or magnetic resonance (MR) imaging.


Options:
A: 90-day global disability assess via the modified Rankin Scale score (mRS) (2 years)
B: 90-day Global Disability Assessed Via the Blinded Evaluation of Modified Rankin Score (mRS). (90 days)
C: The Modified Rankin Scale Score (at 90 days post-stroke)
D: Revascularization Status (Post-procedure, immediate=at the end of the procedure, per last angiogram during treatment)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Brief Summary: The purpose of this study is to compare the effectiveness of treating acute ischemic stroke with mechanical embolectomy using the Merci Retriever or the Penumbra System within 8 hours of symptom onset to standard medical treatment, and to identify people who might benefit from mechanical embolectomy by the appearance of stroke on multimodal computerized tomography (CT) or magnetic resonance (MR) imaging.


Options:
A: modified Rankin Scale (mRS) (at 90 days from randomization)
B: clinical (efficacy): favorable modified Rankin Score (less than or equal to 2) (3 months); Rate of symptomatic intracranial hemorrhage (24 hours)
C: The Modified Rankin Scale Score (at 90 days post-stroke)
D: The Distribution of Scores on the Modified Rankin Scale (mRS) at Day 90 (Day 90)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Brief Summary: The purpose of this study is to compare the effectiveness of treating acute ischemic stroke with mechanical embolectomy using the Merci Retriever or the Penumbra System within 8 hours of symptom onset to standard medical treatment, and to identify people who might benefit from mechanical embolectomy by the appearance of stroke on multimodal computerized tomography (CT) or magnetic resonance (MR) imaging.


Options:
A: Reperfusion at 24 hours (CT or MR perfusion imaging) (24 hours post stroke onset); Favourable clinical response at 3 days(National Institutes of Health Stroke Score - NIHSS) (3 days post stroke onset)
B: To assess whether IA thrombolysis, as compared to IV rt-PA, increases survival free of disability (modified Rankin score of zero or 1) at 3 months. (3 months)
C: Shift in the mRS score, defined by a proportional odds model. (90 days)
D: The Modified Rankin Scale Score (at 90 days post-stroke)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar
Brief Summary: The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.


Options:
A: infant pain response, as measured by facial grimacing and changes in heart rate and oxygen saturation during the procedure
B: technical quality of the LP, classified as success or failure. (immediate)
C: pain response to vaccination with Prevnar and Pentacel, as measured by The Modified Behavioral Pain Scale (MBPS) and the Visual Analogue Scale (VAS) (Immediately after vaccination)
D: To measure analgesic effectiveness of the 5 S's (swaddling, side/stomach position, shushing, swinging, and sucking) alone and combined with sucrose, during routine immunizations at 2 and 4 month well child visits. (every 15 sec)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar
Brief Summary: The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.


Options:
A: Neonatal Infant Pain Scale (NIPS) (4-6 minutes. Change of the infants pain during Stage 1-6 of the circumcision.)
B: Hypersensitivity to pain (At 15 month vaccination (Visit 5))
C: Visual Analogue Scale (sevral minutes before and after BTX injections)
D: pain response to vaccination with Prevnar and Pentacel, as measured by The Modified Behavioral Pain Scale (MBPS) and the Visual Analogue Scale (VAS) (Immediately after vaccination)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients
Brief Summary: This study will compare three standard treatment programs commonly offered to patients with breast cancer. The three programs being compared are 1) Mindfulness Meditation-Based Stress Reduction (MBSR), 2)Supportive- Expressive Group Therapy (SET), and 3) A one day stress-management seminar. The purpose of this study is to determine if these three treatments have different effects on psychological well-being, the immune system, and the amount of stress hormones in the bloodstream.


Options:
A: Overall Survival (OS) (From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years); Progression Free Survival (PFS) (From date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date of 12 Mar 2012 or up to approximately 6 years)
B: Pain (From baseline until 6 months)
C: Disease-free Survival (DFS) (Unitil the end of study with a median follow up of 75 months)
D: Psychological:mood, stress, post-traumatic growth, social support, quality of life, spirituality; Physical:cortisol levels (stress hormone)

Answer: D